🔗 Share this article

While the US undertakes unprecedented changes to its vaccination recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning coronavirus vaccinations throughout the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Health officials planned to announce sweeping revisions to the pediatric vaccination calendar in December, synchronizing the US with the Danish immunization schedule, according to reports – a major change that would put the US out of step with much of the world with little proof for benefit. This reveal has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the division this calendar year.

Consolidating Power at the FDA

This interim role might represent a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US to become more similar to Denmark, a nation with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Qualifications

Høeg has no apparent experience in drug development, approval processes or management, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in running a large organization. She has no expertise in industry regulation.”

Former directors of the center would “be deeply familiar with laws and regulations and the science of drug development”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who headed CBER have had.”

CDER has an enormous workload at the FDA, she emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division clears numerous generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and every single one need to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership element to the job, which oversees more than 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” the former official added.

Agency Reaction and Contentious Programs

In response to questions about Dr. Høeg's fitness for the role and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a spokesperson stated that the “concerns rely on inaccurate presumptions”.

“This background aligns with the functions of her job,” the representative explained, pointing to the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that reportedly concerned her predecessors. “By what process are these medications being picked for this voucher program? Who makes the calls?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, except for shots.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, track record, critics observe. She authored a analysis using unconfirmed public submissions to determine the incidence of heart inflammation following Covid immunization. She advised the Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the new administration featured changing rules for new vaccines and ending “unnecessary” vaccines, she stated after the election on a online show. At the agency, Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an thorough true believer who begins with her preconceived notions and tailors the evidence to accommodate the data in a extremely disingenuous, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|